



Committed to therapeutic innovation for the benefit of patients

We are an independent, international pharmaceutical group governed by a non-profit foundation



21600
employees



148
countries

Our R&D is specialized in 5 main therapeutic areas



Cardiovascular diseases



Diabetes



Cancer



Immune-inflammatory diseases



Neuropsychiatric diseases

3 research centers

16 production sites

16 International Centers for Therapeutic Research

30

drug candidates in clinical development

25%


of turnover (excluding generics) invested in R&D

Our drugs are used to treat 94 million patients daily



Turnover of 4.15 billion euros in 2016/2017


Distribution of turnover by geographical area



Distribution of turnover by business area

Servier brand name drugs: 70 %
Generic drugs: 30 %

Distribution of turnover by therapeutic area



Net profit equals 5% of turnover